Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment

References

• Brown S, Banfill K, Aznar MC, et al. The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol. 2019;92(1104):20190524.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced Non-Small cell lung cancer: real-World issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39(39):531–542.
   PubMedGoogle Scholar
• Rocco D, Della Gravara L, Battiloro C, et al. The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Expert Rev Anticancer Ther. 2019;19(7):561–568.
   PubMed Web of Science ®Google Scholar
• Chen L, Nan A, Zhang N, et al. Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. Mol Cancer. 2019;18(1):13.
   PubMed Web of Science ®Google Scholar
• Hsu PC, Jablons DM, Yang CT, et al. Epidermal Growth Factor Receptor (EGFR) pathway, Yes-Associated Protein (YAP) and the regulation of programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC. Int J Mol Sci. 2019;20(15):3821.
   Web of Science ®Google Scholar
• Singhi EK, Horn L, Sequist LV, et al. Advanced Non-Small cell lung cancer: sequencing agents in the EGFR-Mutated/ALK-Rearranged populations. Am Soc Clin Oncol Educ Book. 2019;39(39):e187–e197.
   PubMedGoogle Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic Non-Small cell lung cancer: a review. Jama. 2019;322(8):764–774.
   PubMed Web of Science ®Google Scholar
• Duma N, Santana-Davila R, Molina JR. Non-Small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640.
   PubMed Web of Science ®Google Scholar
• Wang S, Zimmermann S, Parikh K, et al. Current diagnosis and management of Small-Cell lung cancer. Mayo Clin Proc. 2019;94(8):1599–1622.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Anfossi S, Ramapriyan R, et al. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58(4):244–253.
   PubMed Web of Science ®Google Scholar
• Tang XJ, Wang W, Hann SS. Interactions among lncRNAs, miRNAs and mRNA in colorectal cancer. Biochimie. 2019;163:58–72.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Guo YN, Shi K, et al. Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data. Respir Res. 2019;20(1):48.
   PubMed Web of Science ®Google Scholar
• Jiang R, Hu C, Li Q, et al. Sodium new houttuyfonate suppresses metastasis in NSCLC cells through the Linc00668/miR-147a/slug axis. J Exp Clin Cancer Res. 2019;38(1):155.
   PubMed Web of Science ®Google Scholar
• Yang T, Li H, Chen T, et al. LncRNA MALAT1 depressed Chemo-Sensitivity of NSCLC Cells through directly functioning on miR-197-3p/p120 catenin axis. Mol Cells. 2019;42(3):270–283.
   PubMed Web of Science ®Google Scholar
• Hu X, Xu S, Chen Y, et al. Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis. Leukemia. 2019;33(5):1090–1101.
   PubMed Web of Science ®Google Scholar
• Kang MR, Park KH, Yang JO, et al. miR-6734 Up-Regulates p21 gene expression and induces cell cycle arrest and apoptosis in colon cancer cells. PLoS One. 2016;11(8):e0160961.
   PubMed Web of Science ®Google Scholar
• Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79(1):351–379.
   PubMed Web of Science ®Google Scholar
• Huang Y. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med. 2018;22(12):5768–5775.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen G, He J, et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer. Bioengineered. 2021;12(1):325–340.
   PubMed Web of Science ®Google Scholar
• Han J, Li S, Feng Y, et al. A novel circular RNA (hsa_circ_0059930)-mediated miRNA-mRNA axis in the lipopolysaccharide-induced acute lung injury model of MRC-5 cells. Bioengineered. 2021;12(1):1739–1751.
   PubMed Web of Science ®Google Scholar
• Tong X, Su P, Yang H, et al. MicroRNA-598 inhibits the proliferation and invasion of non-small cell lung cancer cells by directly targeting ZEB2. Exp Ther Med. 2018;16(6):5417–5423.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liang S, Yu Y, et al. Knockdown of SNHG12 suppresses tumor metastasis and epithelial-mesenchymal transition via the Slug/ZEB2 signaling pathway by targeting miR-218 in NSCLC. Oncol Lett. 2019;17(2):2356–2364.
   PubMed Web of Science ®Google Scholar
• Cui J, Pan G, He Q, et al. MicroRNA-545 targets ZEB2 to inhibit the development of non-small cell lung cancer by inactivating Wnt/β-catenin pathway. Oncol Lett. 2019;18(3):2931–2938.
   PubMed Web of Science ®Google Scholar
• Jiao A, Sui M, Zhang L, et al. MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator. Mol Med Rep. 2016;13(4):3349–3355.
   PubMed Web of Science ®Google Scholar
• Li C, Wan L, Liu Z, et al. Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. Cancer Lett. 2018;418:185–195.
   PubMed Web of Science ®Google Scholar
• Del Re M, Crucitta S, Gianfilippo G, et al. Understanding the mechanisms of resistance in EGFR-Positive NSCLC: from tissue to liquid biopsy to guide treatment strategy. Int J Mol Sci. 2019;20(16):3951.
   PubMed Web of Science ®Google Scholar
• Le X, Puri S, Negrao MV, et al. Landscape of EGFR-Dependent and -Independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-Mutant NSCLC. Clin Cancer Res. 2018;24(24):6195–6203.
   PubMed Web of Science ®Google Scholar
• Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.
   PubMed Web of Science ®Google Scholar
• Zhang CC, Li Y, Feng XZ, et al. Circular RNA circ_0001287 inhibits the proliferation, metastasis, and radiosensitivity of non-small cell lung cancer cells by sponging microRNA miR-21 and up-regulating phosphatase and tensin homolog expression. Bioengineered. 2021;12(1):414–425.
   PubMed Web of Science ®Google Scholar
• Chen L, Han X, Hu Z, et al. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis. Cancer Chemother Pharmacol. 2019;83(5):921–931.
   PubMed Web of Science ®Google Scholar
• Wang N, Song L, Xu Y, et al. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. EBioMedicine. 2019;47:65–77.
   PubMed Web of Science ®Google Scholar
• Shi ZM, Wang L, Shen H, et al. Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. Oncogene. 2017;36(18):2577–2588.
   PubMed Web of Science ®Google Scholar
• Wu DM, Zhang T, Liu YB, et al. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling. Cell Death Dis. 2019;10(5):349.
   PubMed Web of Science ®Google Scholar
• Pinyol R, Montal R, Bassaganyas L, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68(6):1065–1075.
   PubMed Web of Science ®Google Scholar
• Li X, Li C, Bi H, et al. Targeting ZEB2 by microRNA-129 In Non-Small cell lung cancer suppresses cell proliferation, invasion and migration via regulating Wnt/β-Catenin signaling pathway and Epithelial-Mesenchymal transition. Onco Targets Ther. 2019;12:9165–9175.
   PubMed Web of Science ®Google Scholar
• MacDonagh L, Gray SG, Breen E, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018;428:117–126.
   PubMed Web of Science ®Google Scholar
• Dong Y, Xu T, Zhong S, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci. 2019;239:116984.
   PubMed Web of Science ®Google Scholar
• Tang H, Han X, Li M, et al. Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519a. Biochimie. 2019;162:134–143.
   PubMed Web of Science ®Google Scholar
• Rao C, Miao X, Zhao G, et al. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomed Pharmacother. 2019;114:108662.
   PubMed Web of Science ®Google Scholar
• Shi SL, Zhang ZH. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway. Neoplasma. 2019;66(5):756–765.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li F, Ma D, et al. MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2. Mol Med Rep. 2019;20(4):3519–3526.
   PubMed Web of Science ®Google Scholar